Table 3 ICIs combined with target therapies involving clinical trials against GCs
Trial | Patient feature | Agent | Target | Phase | Outcomes | Ref. |
|---|---|---|---|---|---|---|
NCT02942329 | Advanced hepatocellular carcinoma (HCC), GC/EGJC | Camrelizumab + apatinib | PD-1, VEGF2 | I | SHR-1210 and apatinib combination therapy present manageable toxicity | Xu et al. (2019) [48] |
CP-MGAH22-05 (NCT02689284) | Locally advanced or metastatic, resectable, HER2+ GC | Margetuximab + pembrolizumab | PD-1, HER2 | Ib/II | Synergistic antitumour activity with the combination of margetuximab with anti-pembrolizumab | Catenacci et al. (2019) [12] |
EGONIVO (EPOC1603) | GC and colorectal cancer | Regorafenib + nivolumab | PD-1, VEGF2 | Ib | Combination of regorafenib and nivolumab presented a manageable safety profile and encouraging antitumor activity | Fukuoka et al. (2019) [61] |
EPOC1706 | Metastatic or recurrent GC/EGJC | Lenvatinib + pembrolizumab | PD-1, VEGF2 | II | Promising anti-tumor activity with an acceptable safety profile in patients with advanced GC | Kawazoe et al. (2020) [59] |
LEAP-005 (NCT03797326 | Advanced GC | Lenvatinib + pembrolizumab | PD-1, VEGF2 | II | PFS with 2.5 months (1.8–4.2) and OS with 5.9 months | Villanueva et al. (2020) [60] |
NCT02572687 | Measurable GC | Ramucirumab + durvalumab | PD-1, VEGF2 | Ia/b | Ramucirumab/durvalumab exhibited manageable safety and antitumor activity | Bang et al. (2020) [62] |